Therapeutic effect of increased openness: Investigating mechanism of action in MDMA-assisted psychotherapy
- PMID: 28635375
- PMCID: PMC5544120
- DOI: 10.1177/0269881117711712
Therapeutic effect of increased openness: Investigating mechanism of action in MDMA-assisted psychotherapy
Abstract
A growing body of research suggests that traumatic events lead to persisting personality change characterized by increased neuroticism. Relevantly, enduring improvements in Post-Traumatic Stress Disorder (PTSD) symptoms have been found in response to 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy. There is evidence that lasting changes in the personality feature of "openness" occur in response to hallucinogens, and that this may potentially act as a therapeutic mechanism of change. The present study investigated whether heightened Openness and decreased Neuroticism served as a mechanism of change within a randomized trial of MDMA-assisted psychotherapy for chronic, treatment-resistant PTSD. The Clinician-Administered PTSD Scale (CAPS) Global Scores and NEO PI-R Personality Inventory (NEO) Openness and Neuroticism Scales served as outcome measures. Results indicated that changes in Openness but not Neuroticism played a moderating role in the relationship between reduced PTSD symptoms and MDMA treatment. Following MDMA-assisted psychotherapy, increased Openness and decreased Neuroticism when comparing baseline personality traits with long-term follow-up traits also were found. These preliminary findings suggest that the effect of MDMA-assisted psychotherapy extends beyond specific PTSD symptomatology and fundamentally alters personality structure, resulting in long-term persisting personality change. Results are discussed in terms of possible mechanisms of psychotherapeutic change.
Keywords: MDMA; NEO personality; openness; pharmacotherapy; posttraumatic stress disorder (PTSD); psychotherapy; treatment outcome.
Conflict of interest statement
Figures
![Figure 1.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5544120/bin/10.1177_0269881117711712-fig1.gif)
![Figure 2.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5544120/bin/10.1177_0269881117711712-fig2.gif)
Similar articles
-
Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study.J Psychopharmacol. 2013 Jan;27(1):28-39. doi: 10.1177/0269881112456611. Epub 2012 Nov 20. J Psychopharmacol. 2013. PMID: 23172889 Free PMC article. Clinical Trial.
-
3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial.Lancet Psychiatry. 2018 Jun;5(6):486-497. doi: 10.1016/S2215-0366(18)30135-4. Epub 2018 May 1. Lancet Psychiatry. 2018. PMID: 29728331 Clinical Trial.
-
Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.Psychopharmacology (Berl). 2020 Aug;237(8):2485-2497. doi: 10.1007/s00213-020-05548-2. Epub 2020 Jun 4. Psychopharmacology (Berl). 2020. PMID: 32500209 Free PMC article. Clinical Trial.
-
MDMA-Assisted Psychotherapy for Treatment of Posttraumatic Stress Disorder: A Systematic Review With Meta-Analysis.J Clin Pharmacol. 2022 Apr;62(4):463-471. doi: 10.1002/jcph.1995. Epub 2021 Nov 28. J Clin Pharmacol. 2022. PMID: 34708874 Review.
-
Progress and promise for the MDMA drug development program.Psychopharmacology (Berl). 2018 Feb;235(2):561-571. doi: 10.1007/s00213-017-4779-2. Epub 2017 Nov 20. Psychopharmacology (Berl). 2018. PMID: 29152674 Review.
Cited by
-
Effect of MDMA-assisted therapy on mood and anxiety symptoms in advanced-stage cancer (EMMAC): study protocol for a double-blind, randomised controlled trial.Trials. 2024 May 21;25(1):336. doi: 10.1186/s13063-024-08174-x. Trials. 2024. PMID: 38773523 Free PMC article.
-
Depression with comorbid borderline personality disorder - could ketamine be a treatment catalyst?Front Psychiatry. 2024 Apr 29;15:1398859. doi: 10.3389/fpsyt.2024.1398859. eCollection 2024. Front Psychiatry. 2024. PMID: 38742125 Free PMC article. Review.
-
Subjective long-term emotional and social effects of recreational MDMA use: the role of setting and intentions.Sci Rep. 2024 Feb 10;14(1):3434. doi: 10.1038/s41598-024-51355-6. Sci Rep. 2024. PMID: 38341455 Free PMC article.
-
Cross-validation of the ego dissolution scale: implications for studying psychedelics.Front Neurosci. 2023 Dec 5;17:1267611. doi: 10.3389/fnins.2023.1267611. eCollection 2023. Front Neurosci. 2023. PMID: 38116073 Free PMC article.
-
MDMA-Based Psychotherapy in Treatment-Resistant Post-Traumatic Stress Disorder (PTSD): A Brief Narrative Overview of Current Evidence.Diseases. 2023 Nov 3;11(4):159. doi: 10.3390/diseases11040159. Diseases. 2023. PMID: 37987270 Free PMC article. Review.
References
-
- American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Arlington, VA: American Psychiatric Association.
-
- Beltran RO, Silove D. (1999) Expert opinions about the ICD-10 category of enduring personality change after catastrophic experience. Comprehensive Psychiatry 40: 396–403. - PubMed
-
- Beltran RO, Llewellyn GM, Silove D. (2008) Clinicians’ understanding of International Statistical Classification of Diseases and Related Health Problems, 10th Revision diagnostic criteria: F62.0 enduring personality change after catastrophic experience. Comprehensive Psychiatry 49: 593–602. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous